N

Neuphoria Therapeutics Inc
NASDAQ:NEUP

Watchlist Manager
Neuphoria Therapeutics Inc
NASDAQ:NEUP
Watchlist
Price: 3.88 USD 4.02% Market Closed
Market Cap: 20.9m USD

Operating Margin
Neuphoria Therapeutics Inc

-7.2%
Current
-2 445%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-7.2%
=
Operating Profit
-1.1m
/
Revenue
15.6m

Operating Margin Across Competitors

No Stocks Found

Neuphoria Therapeutics Inc
Glance View

Market Cap
20.9m USD
Industry
Biotechnology

Neuphoria Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Burlington, Massachusetts and currently employs 8 full-time employees. Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The firm is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.

NEUP Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-7.2%
=
Operating Profit
-1.1m
/
Revenue
15.6m
What is the Operating Margin of Neuphoria Therapeutics Inc?

Based on Neuphoria Therapeutics Inc's most recent financial statements, the company has Operating Margin of -7.2%.

Back to Top